2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1903 Defining the role of ctDNA monitoring in a risk stratified clinical trial for posttransplant lymphoproliferative disorder (PTLD)

Jennifer Effie Amengual, MD, Joe Gaillard Schroers-Martin, MD2, Hua-Jay Jeffery Cherng, MD3, Yuxuan Chen, PhD4, Ted Piorczynski, PhD5, Seda S. Tolu, MD6, Barbara Pro, MD7, Ranjana Advani, MD8, Neel Gupta, MD9, Manuela Orjuela, MD10, Lianna J Marks, MD11, Manuel Pazos, BS, MS12, Navika Shukla, MD13, Shuyu Shi, PhD14, Naomi Sender15, Sarah Sedycias16, Megan Nieman17, Anthony Yu18, Esha Patel19, Ash A. Alizadeh, MD, PhD20
1 Columbia University Irving Medical Center, New York, New York, United States
2 Stanford University, Stanford, California, United States
3 Columbia University Irving Medical Center, New York, New York, United States
4 Columbia University Irving Medical Center, New York, New York, United States
5 Columbia University Irving Medical Center, New York, New York, United States
6 Columbia University Irving Medical Center, New York, New York, United States
7 Columbia University Irving Medical Center, New York, New York, United States
8 Stanford University, Stanford, California, United States
9 Stanford University, Stanford, California, United States
10 Columbia University Irving Medical Center, New York, New York, United States
11 Stanford University, Stanford, California, United States
12 Columbia University Irving Medical Center, New York, New York, United States
13 Stanford University, Stanford, California, United States
14 Stanford University, Stanford, California, United States
15 Columbia University Irving Medical Center, New York, New York, United States
16 Columbia University Irving Medical Center, New York, New York, United States
17 Columbia University Irving Medical Center, New York, New York, United States
18 Stanford University, Stanford, California, United States
19 Stanford University, Stanford, California, United States
20 Stanford University, Stanford, California, United States

Posttransplant lymphoproliferative disorder (PTLD) are a group of lymphomas that arise following solid organ (SOT) or allogeneic stem cell transplant. Current treatment for PTLD follows a risk-stratified sequential approach starting with rituximab induction. High-risk patients go on to receive chemoimmunotherapy; while low-risk patients receive rituximab consolidation. Stratification approaches use clinical variables that imperfectly predict relapse. While 25% of patients avoid chemotherapy, many low-risk patients have a short duration of response with a 2-year PFS of 56%.The remaining 75% of high-risk patients receiving chemoimmunotherapy have poor outcomes with a 2 yr OS of 59%.

SOT recipients share clinical characteristics with patients with HIV/AIDS: impaired T cell function, concomitant medications with multiple drug-drug interactions, numerous comorbidities, and higher rates of oncogenic infections. In AIDS-related DLBCL, R-CHOP underperforms and leads to excessive toxicity. Dose modified (DM) R-EPOCH was explored by the AIDS malignancy consortium and led to a 73% CR rate, 2-year OS of 70% and a treatment related mortality of 9.8%. Given the similarities between AIDS-related DLBCL and B-cell PTLD, first line DM R-EPOCH consolidation may better serve patients with high-risk PTLD.

Disease assessment with circulating tumor DNA (ctDNA) has created opportunities to prognosticate and guide on-treatment decision making in non-transplant related lymphomas. The utility of quantifying measurable residual disease (MRD) with ctDNA has not been systematically or prospectively studied in the context of PTLD. By validating this breakthrough technology in PTLD, where risk-stratified treatment is standard of care but imperfect, we aim to precisely define and stratify which patients truly require chemotherapy.

This is an open label, single arm, multicenter phase 2 study of the efficacy of a risk stratified approach to treating PTLD using DM R-EPOCH for high-risk patients while maintaining low-risk patients on rituximab alone (NCT06954805). The primary objective is end of treatment (EOT) CR rate. Secondary objectives include: incidence of adverse events; 1-yr EFS, OS, PFS; determining the rate of undetectable ctDNA MRD throughout the treatment course and its association with CR and 1-yr OS. Exploratory objectives include: T cell receptor repertoire and phenotype; the emergence of oncogenic viral DNA; and assessment of quality of life (QOL) through collection of patient reported outcomes.

Key inclusion criteria include: untreated CD20+ B-cell PTLD (both poly- and monomorphic); age≥15; adequate organ function; no CNS disease. All patients will have immunosuppression reduced per transplant physician discretion and be treated with induction rituximab 375 mg/m2 weekly x 4. Response will be assessed by PET/CT per Lugano classification. Patients with a CR or PR without high-risk features will be treated with rituximab consolidation every 21 days for 4 cycles. Patients with stable disease, progressive disease or PR with residual bulky disease and/or underlying high-risk cytogenetics will be deemed high-risk and subsequently receive 4 cycles of DM R-EPOCH as per the AIDS malignancy protocol with cyclophosphamide starting dose at 187-375 mg/m2 and other chemotherapy agents adjusted for organ function. All patients treated with DM R-EPOCH will receive G-CSF, fluoroquinolone, PJP, viral and fungal prophylaxis. Patients will have peripheral blood collected at pre-treatment, end of induction, mid-consolidation, EOT, 6- and 12m post EOT time-points to evaluate 1) viral cell free DNA and ctDNA quantification; 2) flow cytometry and T cell sequencing. QOL will be measured by EORTC QLQ C30 at baseline, following rituximab induction, C3D1 consolidation, EOT and 6- and 12m post EOT.

Assuming a CR rate of 30% with standard treatment, a goal CR rate for high-risk patients is 60%. A Simon minimax 2-stage design was used. Given the historical CR rate to rituximab induction is 25%, 27 total patients will need to be enrolled to assess efficacy of DM R-EPOCH. Assuming a 10% drop-out rate, total 30 patients are required. This design has a power of 85% using an α of 0.05.

This clinical study addresses an unmet need for improving stratification and treatment efficacy for patients with PTLD. Funding support: Blood Cancer United

Jennifer Effie Amengual, MD: AstraZeneca - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony)